Petrelintide
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Roche · Phase 2 · Completed · Enrollment 221
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment A: Petrelintide Dose 1 | n/r | n/r | n/r | n/r |
| Treatment B: Petrelintide Placebo Dose 1 | n/r | n/r | n/r | n/r |
| Treatment C: Petrelintide Dose 2 | n/r | n/r | n/r | n/r |
| Treatment D: Petrelintide Placebo Dose 2 | n/r | n/r | n/r | n/r |
| Treatment E: Petrelintide Dose 3 | n/r | n/r | n/r | n/r |
| Treatment F: Petrelintide Placebo Dose 3 | n/r | n/r | n/r | n/r |
Not shown
- Treatment A: Petrelintide Dose 1: endpoint not reported
- Treatment B: Petrelintide Placebo Dose 1: endpoint not reported
- Treatment C: Petrelintide Dose 2: endpoint not reported
- Treatment D: Petrelintide Placebo Dose 2: endpoint not reported
- Treatment E: Petrelintide Dose 3: endpoint not reported
- Treatment F: Petrelintide Placebo Dose 3: endpoint not reported